Skip to main content
CELL BIOTECH CO ., LTD logo

CELL BIOTECH CO ., LTD — Investor Relations & Filings

Ticker · 049960 ISIN · KR7049960008 KO Manufacturing
Open in API
Filings indexed 189 across all filing types
Latest filing 2024-04-03 Director's Dealing
Country KR South Korea
Listing KO 049960

About CELL BIOTECH CO ., LTD

https://www.cellbiotech.com/

CELL BIOTECH CO., LTD. is a biotechnology company specializing in the research, development, and manufacturing of probiotic solutions. With over three decades of experience, the company leverages its proprietary, worldwide-patented dual-coating technology, which is designed to ensure a higher survival rate for probiotic strains as they pass through the gastrointestinal tract. The company develops and utilizes its own GRAS (Generally Recognized as Safe) certified strains for its products. Its business encompasses the production of finished consumer products, such as the DUOLAC brand, and providing customized OEM/ODM services for the pharmaceutical and food supplement sectors.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details a transaction (장내매수 - open market purchase) of shares by an executive (은유민) of the company Cellbiotech. This is a standard regulatory filing for insider trading/director's dealing, which corresponds to the 'DIRS' category.
2024-04-03 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides the official outcomes of the shareholder meeting held on 2024-03-27. It details the approval of financial statements, dividend declarations, and board/management appointments. This falls directly under the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-03-27 Korean
투자판단관련주요경영사항(임상시험계획승인신청등결정) (대장암치료제 PP-P8 제1상 임상시험계획(IND) 승인)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from a Korean company (Cell Biotech) regarding the approval of a Phase 1 clinical trial for a colorectal cancer treatment (PP-P8). It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) filed with the Korea Exchange (KRX). Since it details a specific regulatory event (clinical trial approval) and does not fit into specific categories like financial reports or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2024-03-21 Korean
사업보고서 (2023.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive 'Audit Report' (감사보고서) for Cell Biotech, covering the fiscal year 2023. It includes the independent auditor's report, consolidated financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes. It is not an Annual Report (10-K) as it lacks the broader management discussion and analysis (MD&A) or business overview typically found in a full 10-K, and it is not an Earnings Release as it is a formal, audited financial document. FY 2023
2024-03-19 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) submitted to the Korea Exchange (KRX). It provides a summary of financial data, audit opinions, and key financial metrics (assets, liabilities, equity, profit/loss) for the current and previous fiscal years. While it contains financial data, it is a standardized regulatory disclosure form used to announce the receipt and submission of the audit report, rather than the full 10-K annual report document itself. Therefore, it is classified as a Regulatory Filing (RNS). FY 2023
2024-03-19 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Cell Biotech. It contains the meeting agenda, date, location, and detailed financial statements (balance sheets and income statements) for the 29th fiscal year. This type of document is a standard proxy statement/information circular provided to shareholders to inform them of upcoming votes and provide necessary financial context for those votes. In the context of the provided categories, this fits the definition of a Proxy Solicitation & Information Statement.
2024-03-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.